A recent study published in The Journal of Nutrition reported that a novel food supplement had anti-inflammatory effects in adults recently diagnosed with COVID-19 who were unvaccinated and nonhospitalized.

Inflammatory mechanisms are crucial to optimal resolution of infectious conditions. Yet, overreactive immune responses can inhibit protective defenses, and can contribute to inflammatory complications and severity.  Because inflammation is at the core of COVID-19 severity, strategies to control inflammation are considered a key approach for mitigating COVID-19 complications.

Palmitoylethanolamide (PEA), a chemical made from fat and found naturally in foods such as egg yolks, peanuts, and soybeans, has been documented as being beneficial for reducing inflammation. PEA has been utilized in several trials to treat influenza and the common cold and was shown to be effective in treating upper respiratory infections. Given the parallels between COVID-19 and the mechanisms by which PEA has been successful as an immunomodulator, a research team at Arizona State University aimed to examine the effects of PEA on proinflammatory biomarkers in adults recently diagnosed with COVID-19 who were unvaccinated and nonhospitalized.

A total of 60 participants in this double-blind randomized placebo-controlled trial received 600 mg of commercially available PEA called Levagen+ or placebo tablets twice daily for 4 weeks. Inflammatory biomarkers were measured at baseline and upon completion of the study. After 4 weeks of supplementation, inflammatory biomarkers were significantly reduced in the treatment group compared to those in the control group. 

The reduction in inflammatory biomarkers in adults recently diagnosed with COVID-19 suggests that PEA may exert anti-inflammatory actions and possibly reduce the severity of COVID-19. Thus, Levagen+ administration may offer a degree of relief from inflammatory symptoms associated with COVID-19 as well as other chronic conditions.


Samantha N Fessler, Li Liu, Yung Chang, Theresa Yip, Carol S Johnston, Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial, The Journal of Nutrition, Volume 152, Issue 10, October 2022, Pages 2218–2226, https://doi.org/10.1093/jn/nxac154.

Images via canva.com.